SteadyMed Therapeutics Finds $3M In Working Capital
San Ramon-based SteadyMed Therapeutics, a developer of biopharmaceuticals to treat Pulmonary Arterial Hypertension (PAH), has raised $3M in a term loan from Square 1 Bank. Square 1 Bank said the loan will go towards working capital, to help the firm continue development of its technology. Terms of the loan were not announced by Square 1.
posted on Monday, April 8, 2013
Related companies:
SteadyMed Therapeutics
Related stories:
> Iconic Therapeutics Finds $20M
> Global Blood Therapeutics Finds $48M
> InteKrin Therapeutics Gets Investment
> PEAR Therapeutics Gets $50M For Treating Substance Abuse With Software
> Stanford Spinout SiteOne Therapeutics Gets Funding
silicontap.com Home